Rodrigo Paredes de la Fuente

Dr. Rodrigo Paredes de la Fuente

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
RFRodrigo Paredes de la Fuente
Rodrigo Paredes de la Fuente
RBRoberto Borea
Roberto Borea
FDFrancesco Drago
Francesco Drago
ARAlessandro Russo
Alessandro Russo
GNGiovanni Nigita
Giovanni Nigita
Christian RolfoChristian Rolfo
Christian Rolfo
The tumor microenvironment (TME) plays a crucial role in shaping the response to immunotherapy in non-small cell lung cancer (NSCLC). While immune checkpoint inhibitors (ICIs) have revolutionized NSCLC treatment, a significant proportion of patients exhibit primary or acquired resistance. Emerging evidence highlights the role of specific genetic alterations, Kelch-like ECH-associated protein 1 (KEAP1), SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 4 (SMARCA4), and phosphatase and tensin homolog (PTEN) mutations, in driving immune evasion and limiting the effectiveness of ICIs. KEAP1 mutations, through constitutive nuclear factor erythroid 2-related factor 2 activation, promote oxidative stress adaptation and metabolic reprogramming, creating an immune-excluded TME that reduces T-cell infiltration. SMARCA4 loss disrupts chromatin remodeling and epigenetic regulation, impairing antigen presentation and fostering a poorly immunogenic tumor phenotype. PTEN inactivation, by dysregulating the PI3K/AKT pathway, enhances tumor proliferation while contributing to an immunosuppressive cytokine milieu. The presence of these mutations is associated with poor outcomes, independent of tumor mutational burden or programmed death-ligand 1 expression, and their co-occurrence, particularly with KRAS and STK11, further compounds resistance. In this review, we explore the biological impact of KEAP1, SMARCA4, and PTEN mutations on the immune landscape of NSCLC, their implications for immunotherapy resistance, and potential strategies to overcome these barriers. As precision oncology advances, identifying therapeutic vulnerabilities in these genetically defined subgroups will be critical to improving patient outcomes and expanding the efficacy of immunotherapy in NSCLC.

1 July 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
JLJames Lyon
James Lyon
SOSoravis Osataphan
Soravis Osataphan
VBVaibhav Birda
Vaibhav Birda
BRBrian Russell
Brian Russell
CECharly Edmiston
Charly Edmiston
MPMary Linton B Peters
Mary Linton B Peters
PURPOSE: Methylthioadenosine phosphorylase ( MTAP ) loss is a common genomic event in cancer and is associated with an immunologically cold phenotype. Recent research has highlighted a synthetic lethality of MTAP loss when combined with PMRT5 or MAT2A inhibition. Although contemporary somatic genomic testing now routinely includes MTAP status, the clinicogenomic characteristics of MTAP loss in cholangiocarcinoma (CCA) remain largely undefined. In this study, we examine the genomic profiles, clinical features, and survival outcomes of MTAP loss CCA. METHODS: This is a single-center retrospective cohort study of patients with CCA from December 2017 to January 2024. Somatic genomics alterations were assessed using targeted next-generational sequencing with FoundationOne CDx. Patient demographics, tumor characteristics, treatment history, and overall survival (OS) were retrospectively collected. Genomics coalterations were assessed using the Fisher exact test. Multivariate Cox proportional hazards regression analysis was used to assess the relationship between MTAP status and OS. RESULTS: Among 94 CCA samples, 89 were successfully sequenced, uncovering 339 genomic alterations, with MTAP loss identified in 16% of cases. It commonly co-occurred with CDKN2A and B loss (93% and 86%, respectively) and was not associated with FGF2R rearrangement, IDH1 mutation, or human epidermal growth factor receptor 2 ( ERBB2 ) amplification. Tumor mutational burden were similar between MTAP status. MTAP loss was associated with lower OS (hazard ratio, 3.95 [95% CI, 1.43 to 10.9]; P = .008) after adjustment for key covariates including age, Eastern Cooperative Oncology Group performance status, nodal stage, metastatic spread, resectability, histologic, and line of therapy. CONCLUSION: MTAP loss is common CCA, co-occurred with CDKN2A and CDKN2B loss, and was associated with poor OS. Future effort to exploit this therapeutic vulnerability in MTAP -loss CCA is critical to improve the care of this population.

6 February 2023 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
RFRodrigo Paredes de la Fuente
Rodrigo Paredes de la Fuente
JDJames W Doolin
James W Doolin
MPMary Linton B Peters
Mary Linton B Peters
A previously healthy man in his 60s was diagnosed with a rare histological subtype of pancreatic cancer, adenosquamous carcinoma. After somatic mutation profiling, it was found that the tumour had microsatellite instability status high and a high tumour mutational burden. The patient was started on combination therapy with gemcitabine, nab-paclitaxel and pembrolizumab. Tumour size and biomarkers showed a dramatic response eventually leading to the patient being transitioned to maintenance therapy with pembrolizumab. The patient has demonstrated continued response since the start of the treatment. This is the first report in the literature showing a sustained response in this type of neoplasm that was treated with a checkpoint inhibitor, and thus adds to the evidence supporting universal somatic testing in all pancreatic cancers for a tailored approach to therapy.

31 August 2026 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
RFRodrigo Paredes de la Fuente
Rodrigo Paredes de la Fuente
RBRoberto Borea
Roberto Borea
DEDiego Enrico
Diego Enrico
KSKatherine Santana
Katherine Santana
LWLexi Weintraub
Lexi Weintraub
CRChristian Rolfo
Christian Rolfo

1 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
RFRodrigo Paredes de la Fuente
Rodrigo Paredes de la Fuente
SSSantiago Sucre
Santiago Sucre
CPCristina Ponce
Cristina Ponce
ARAhmed Anwer Ali Rattani
Ahmed Anwer Ali Rattani
MPMary Linton B Peters
Mary Linton B Peters
(1) Background: Pancreatic ductal adenocarcinoma (PDAC) has low survival rates despite treatment advancements. Aim: This study aims to show how molecular profiling could possibly guide personalized treatment strategies, which may help improve survival outcomes in patients with PDAC. (2) Materials and Methods: A retrospective analysis of 142 PDAC patients from a single academic center was conducted. Patients underwent chemotherapy and next-generation sequencing for molecular profiling. Key oncogenic pathways were identified using the Reactome pathway database. Survival analysis was performed using Kaplan–Meier curves and Cox Proportional Hazards Regression. (3) Results: Patients mainly received FOLFIRINOX (n = 62) or gemcitabine nab-paclitaxel (n = 62) as initial chemotherapy. The median OS was 13.6 months. Longer median OS was noted in patients with NOTCH (15 vs. 12.3 months, p = 0.007) and KIT pathway mutations (21.3 vs. 12.12 months, p = 0.04). Combinatorial pathway analysis indicated potential synergistic effects on survival. In the PFS, PI3K pathway (6.6 vs. 5.7 months, p = 0.03) and KIT pathway (10.3 vs. 6.2 months, p = 0.03) mutations correlated with improved PFS within the gemcitabine nab-paclitaxel subgroup. (4) Conclusions: Molecular profiling could play a role in PDAC for predicting outcomes and responses to therapies like FOLFIRINOX and gemcitabine nab-paclitaxel. Integrating genomic data into clinical decision-making can benefit PDAC treatment, though further validation is needed to fully utilize precision oncology in PDAC management.

30 September 2026 in Revista de la Facultad de Medicina Humana
Verified
Journal Article
Closed access
CACamila Anton
Camila Anton
PAPedro Aro
Pedro Aro
RFRodrigo Paredes de la Fuente
Rodrigo Paredes de la Fuente
BSBilly Sanchez-Jacinto
Billy Sanchez-Jacinto
CTCarmen Tokumura
Carmen Tokumura
Introduction: Some complete blood count–derived indices could be useful for assessing hemoglobinization abnormalities. Objective: To evaluate the diagnostic performance of the microcytic anemia factor (MAF) and low hemoglobin density (LHD%) for identifying hemoglobinization abnormalities consistent with iron-restricted erythropoiesis, using Ret-He <28 pg as the functional reference standard, in blood donor candidates. Methods: A retrospective cross-sectional diagnostic accuracy study was conducted, including 227 blood donor candidates evaluated at the Hemotherapy and Blood Bank Service of Hospital Cayetano Heredia, Lima, Peru. Participants were classified according to Ret-He <28 pg and Ret-He ≥28 pg. MAF and LHD% were calculated from complete blood count parameters. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis, and the area under the curve (AUC), sensitivity, and specificity were estimated. Results: Overall, 17.2% (39/227) of blood donor candidates had Ret-He 5.60, a sensitivity of 92.3%, and a specificity of 84.6%. No statistically significant difference was observed between the two ROC curves. Conclusions: MAF and LHD% showed good diagnostic performance for identifying low reticulocyte hemoglobinization in blood donor candidates. LHD% showed a more favorable screening profile because of its higher sensitivity, whereas MAF showed higher specificity.